Sign in

    Jayna Renee Francis

    Research Analyst at UBS

    Jayna Renee Francis is an analyst at UBS Securities LLC, serving as a registered broker with oversight by FINRA and based at the firm’s New York headquarters. While primary sources confirm her current position and regulatory credentials, public records do not specify her coverage universe, exact seniority, performance metrics, or targeted sector focus. She began her professional tenure in the financial industry with UBS and maintains good standing as a registered securities professional with CRD# 7946520. Francis holds all necessary FINRA registrations to function as an analyst and broker at UBS Securities LLC.

    Jayna Renee Francis's questions to TREACE MEDICAL CONCEPTS (TMCI) leadership

    Jayna Renee Francis's questions to TREACE MEDICAL CONCEPTS (TMCI) leadership • Q1 2025

    Question

    Jayna Renee Francis of UBS requested a breakdown of the assumptions for the high and low ends of the full-year revenue guidance and asked about the drivers of operating leverage to achieve adjusted EBITDA breakeven in 2025.

    Answer

    Mark Hair, Chief Financial Officer, stated that the company is comfortable at the midpoint of its guidance range, with the high end being achievable through faster-than-expected adoption of the new comprehensive bunion solutions. For profitability, he cited three consecutive quarters of adjusted EBITDA improvement driven by operational efficiencies, particularly in sales and marketing, while reaffirming the commitment to reduce cash burn by 50% in 2025 and continuing to invest in R&D.

    Ask Fintool Equity Research AI